Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)

NCT01394354 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma in Relapse

Interventions

DRUG: Vorinostat
DRUG: Bortezomib
DRUG: Doxorubicin
DRUG: Dexamethasone

Sponsor

University Hospital Freiburg

Collaborators

[object Object]
[object Object]